Kailera Therapeutics announces US$600 million Series B financing
Torys acted as counsel to CPP Investments with a team that included Stefan Stauder, Konata Lake, Michele Clarkin, Shane Thomas and Sophia Desmond (corporate/financing) and Scott Semer (tax).
On October 14, 2025, Kailera Therapeutics, Inc. (“Kailera”) announced a US$600 million Series B financing led by new investor Bain Capital Private Equity. The financing will be fully funded at closing and will support the advancement of Kailera’s leading obesity portfolio, including a global Phase 3 clinical program of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss.
Additional new investors in the Series B round comprise leading mutual funds and investors, including Adage Capital Management LP, Canada Pension Plan Investment Board (“CPP Investments”), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority (“QIA”), Royalty Pharma, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price Associates, Inc., and an undisclosed large mutual fund. Kailera’s existing investors, Atlas Venture, Bain Capital Life Sciences, RTW Investments, and Sirona Capital, also participated in the round.
Further information can be found on Globe Newswire’s website.
Kailera is a clinical-stage biopharmaceutical company developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable dual GLP-1/GIP receptor agonist that has demonstrated positive clinical trial results in obesity in China.